Recombinant varicella zoster virus glycoprotein e antigen (as01b adjuvanted) vaccine
Brand: Shingrix
PBAC's latest decision on Recombinant varicella zoster virus glycoprotein e antigen (as01b adjuvanted) vaccine: Recommended with restriction (2018). Considered for Prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in adults aged 60 years and older, with a five-year catch-up program for ages 60–79 years.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2018
Submissions
1
2018 → 2018
Eligible population
Adults aged 60 years and older (60–69 years, 70–79 years, and 80+ years); healthy/immunocompetent individuals in the pivotal trials, though the product information permits use in immunocompromised patients.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Vaccine efficacy (VE) against HZ and PHN
Pivotal trial size
29,311 patients
Key trials
ZOE-50, ZOE-70, SPS
Comparator
No vaccine (ages 60–69 and 80+); live herpes zoster vaccine (Zostavax) (ages 70–79)
Economic model
CEA
ICER note
No ICER calculated; this is a cost-effectiveness comparison submission but no numeric ICER values are stated in the public text. Economic model details are not disclosed.